The Effects Of Statins On The Treatment Of Many Diseases

In a study conducted in 1985 observing primates, it was determined that the major effect of dietary cholesterol is its LDL raising effects. High intakes of cholesterol increase the number of circulating LDL’s and it can also change its size and composition. [12] It was during this time period that the mechanisms by which SFA are thought to increase blood cholesterol concentrations came about. One mechanism for the increase in LDL cholesterol levels is the suppression of LDL receptor activity. Studies in tissue cultures have shown that increasing the cholesterol content of a cell will down-regulate synthesis of LDL receptors. [13] This will lead to an increase in concentration of blood cholesterol. Another cause for an increase in blood cholesterol concentration through intake of dietary SFA is the composition of the newly secreted lipoproteins. With a high saturated fat intake, the LDL’s become rich in cholesterol esters, leaving the triglycerides in the blood. [14] The use of non-human primates in

Current guidelines state that ezetimibe,is considered the best alternative for LDL reduction and tolerability in statin-intolerant patients and considered an adjuvant in this trial. The primary end point was percentage change from baseline to week 12 in LDL cholesterol. Other end points included measures of safety and tolerability of different doses of AMG145 and AMG145 plus ezetimibe. Other objectives included assessment of the safety and tolerability of 3 different doses of AMG145 and AMG145 plus ezetimibe compared with placebo plus ezetimibe. One hundred sixty patients were randomized into 5 groups, to take AMG 145 as monotherapy once a month at 280mg, 320mg and 420mg, to take AMG 145 420mg once a month with ezetimibe 10mg daily or placebo once a month with ezetimibe 10mg daily. At week 12 the AMG 145 groups had a percent change of blood levels of LDL from baseline from -40.8 % to -50.7 % dose ascending monotherapy and -63.0% with combination with ezetimibe versus -14.8% with combination of placebo and ezetimibe. Reduction in total cholesterol percentwise was from -29.8 % to -37.7 % dose ascending monotherapy and -43.3% with combination with ezetimibe versus -10.7% with combination of placebo and ezetimibe. The overall incidence of all adverse effects was similar among patients receiving

ASSESMENT OF THE EFFECT OF STATINS IN LOWRING THE RISK OF STROKE AND PREVENTING CEREBRAL ISCHEMIA IN PATIENTS WITH HYPERCHOLESTEROLEMIA

J.J. explained her atorvastatin calcium medication is used for treating her high cholesterol. Atorvastatin calcium is an HMG-CoA reductase inhibitor, therefore meaning it lower lipids (fats) in the body (MedlinePlus, 2018). Atorvastatin calcium works by lowering high cholesterol levels (MedlinePlus, 2018). Atorvastatin calcium

The average LDL cholesterol was 93.4% in both groups. after one year of randomization, the mean LDL cholesterol was 69.5 mg/dlfor the simvastatin monotherapy and 53.7 mg/dl for the simvastatin/ezetimibe group. P-value 75 years old) with history of ACS and diabetes.

Familial Hypercholesterolemia is an autosomal dominant genetic disease and so is not preventable. However, the sequelae of FH, such as heart attack and stroke, are preventable when the diagnosis is made early in life. Bouhairie (2015) investigated that lifestyle changes, such as adopting a low saturated fat and zero trans fat diets, and exercising regularly are important. In addition, the risk factors for heart attack and strokes, such as high blood pressure and diabetes, should be treated, and smoking must be avoided. These findings add to my idea that a healthier diet ultimately regulates the bodily functions, and how we are able to maintain our daily lives because of it. Medications are also required for FH treatment. It is recommended that patients start treatment at an earlier age because Familial Hypercholesterolemia can lead towards a decrease in cardiovascular activities and even death in those diagnosed with the disease.

In the United States, more than 2,100 people die from cardiovascular disease each day. According to the American Heart Association, too much cholesterol in a person’s blood can lead to a heart disease and stroke (1). Cholesterol is the most common sterol in animal. Plants also have sterols in their structure, however human enzyme systems can only digest animal sterols (2). Cholesterol is produced in our bodies by the liver (endogenous) or could come from the foods we eat (exogenous). Both kinds are transported to and from the cells by lipoproteins: LDL and HDL. LDL cholesterol is considered to be the ”bad” cholesterol, since it contributes in depositing plaque in the arteries, therefore contributing to atherosclerosis. HDL, on the other hand, is considered to be the” good” cholesterol since it has the opposite effect; it removes the LDL cholesterol from the arteries carrying it back to the liver, therefore reducing risks of atherosclerosis. Maintaining the low levels of LDL and high levels of HDL is extremely important, as HDL is responsible for moving the cholesterol from the blood to the liver whereas LDL is the reason for the build up inside the artery therefore increasing the risk of the cardiovascular diseases.

Statins are competitive inhibitors HMG-CoA reductase, it has been considered as a first line for the treatment of hypercholesterolemia. Their mode of action is by mimicking the substrate molecule HMG-CoA and competes for binding to the HMGCR enzyme. It works by slowing the production rate of mevalonate which responsible for the production of cholesterol molecule.

Fenofibrate is a member of the fibrate class of drugs, and is approved by the FDA for treating dyslipidemia via lowering triglycerides and increasing high density lipoproteins. While fenofibrate is generally well tolerated, there are side effects, one of the more severe ones being myopathies of several varieties, including myalgia, muscle cramps, and rhabdomyolysis.1 Rhabdomyolysis is defined as damage to striated muscle cells that results in their contents being released into the extracellular fluid and circulation, which can lead to myoglobin being excreted in the urine, causing acute kidney injury, failure, and even death if left untreated.2 Rhabdomyolysis is only rarely observed in patients undergoing fenofibrate therapy, and is often present with confounding factors, calling into question the association.2(p927) However, Rhabdomyolysis is also a well known potential side effect of statin drugs, so it is not out of the question that other lipid lowering drugs may have similar effects.1(p909) In this paper, we will look at the current literature surrounding

Along with high blood pressure, high cholesterol levels are regarded as one of the most reliable indicators of possible serious health problems, particularly in the cardio-vascular field. We are told that we should check our cholesterol levels, as many of us already have high cholesterol without being aware of it. We may then need to take…

ADVERSE EFFECTS - Myelosuppression, nausea, vomiting, elevated increased alkaline phosphatase, proteinuria, fever, haematuria, rash, dyspnoea, edema, flu-like symptoms, infection, alopecia, neurotoxicity, renal or liver failure, haemolytic uremic syndrome, capillary leak syndrome, and posterior reversible encephalopathy syndrome.

Statins are like: Lipitor (I take this), Lovastatin, Pravastatin, Crestor, Zocor, Crestor, and Lipitor. One problem Mr. Brown when you take these types of meds you have to come in for blood work about every 3 months. We want to make sure that your liver is not being affected by the MEDs. The side effects that you can have are; Diarrhea or constipation, abdominal pain, cramps, bloating or gas, Nausea, Vomiting, Headache, Drowsiness, Dizziness, and possible Muscle ache or weakness. My opinion Mr. Brown is that having the side effect outweigh having a heart attack, it’s possible that you might not have any reactions to the medicines. Taking these types of medicine are much more a help the hindrance. Lowering your cholesterol is much more important to your health. Mr. Brown there is another option if you want to try. I realize this is not what you had planned, but it is an option, but I want you to come back and she me so we can check your blood cholesterol. You will have to get up and exercise, know more junk snacks and I can put you on a high fiber diet. I will be right here with you, to help in any way. Trust and communication is a priority. I want you to understand your concerns are my concerns and I think this will work out, providing you follow my orders. This disease is a treatable illness and most of the time it can be whipped so long as you get yourself on the right track. You will feel so much better and your

Thirteen years ago, cholesterol-lowering drugs called statins were introduced as a treatment for people with heart disease. In the relatively short amount of time the drug has been available, it has been prescribed to nearly five million people. Originally, statins were introduced to prevent heart attacks and prolong the lives of people with existing heart disease or with a history of heart disease. Recently, however, studies have shown that statins are not only useful for the treatment of heart disease, but are also useful in the lowering of cholesterol levels.

The results of the study reinforce previous findings that back clinical data, advocating for the use of dietary supplements alongside making lifestyle changes. In 1999, a study looking at the effectiveness of Reducol and low fat diet in lowering cholesterol levels was conducted by McGill University in Montreal, Canada. In the study involving 32 subjects, patients who took 1.g a day of Reducol branded sitosterol with sterol combination recorded a remarkable LDL reduction of up to 24% compared to a reduction of 9% for those who relied on low fat diet. In the study, no remarkable increases in plasma sterol were recorded, a fact that suggests the sterols were not absorbed.

Sanofi plans on using antibodies to target PCSK9 which could lead to an alternative to the commonly used statins drug. Out of the 32 patients in the most recent trial, 24 received a single dose of the RNAi drug. The results showed that the expression of PCSK9 dropped to a staggering average, 70% and a 40% decrease of LDL cholesterol levels. If the PCSK9 inhibition drug deems successful it is still not sure whether the drug will perform well from a business aspect.